Table 6.

Author recommendations for level of disease activity required for use of alemtuzumab

Clinical activity

≥2 relapses in previous year

Clinical and MRI activity

1 relapse within the previous year with new MRI activity attributable to MS

1 relapse within the previous year with incomplete recovery associated with an increase of ≥2 new T2 or Gd+ lesions

Cognitive decline with MRI activity attributable to MS

Patients with breakthrough diseasea (activity on clinical or MRI assessments)

Gd ⁺ gadolinium-enhancing, MRI magnetic resonance imaging, MS multiple sclerosis

^aPatients with stable disease for several years who suddenly experience ≥1 relapse with an increase in disability and number of Gd⁺ lesions